Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Receivables (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Receivables for 2 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 93.75% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Dec 2025, down 7.33% year-over-year, with the annual reading at $12.9 million for FY2025, 7.33% down from the prior year.
  • Change in Receivables for Q4 2025 was $10.0 million at Day One Biopharmaceuticals, up from -$3.0 million in the prior quarter.
  • The five-year high for Change in Receivables was $10.0 million in Q4 2025, with the low at -$3.0 million in Q3 2025.